A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Trial Profile

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-087
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Results assessing the health-related quality of life (n=205), presented at the 42nd European Society for Medical Oncology Congress
    • 05 May 2017 According to a Merck AG media release, based on data from the KEYNOTE-087 and KEYNOTE-013 trials European Medicines Agency (EMA) has approved KEYTRUDA (pembrolizumab), for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
    • 24 Mar 2017 The recommendation will be reviewed by the European Commission for marketing authorization in the European Union. A decision on approval is anticipated in the second quarter of 2017, as reported in a Merck & Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top